We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

84 hedge funds and large institutions have $1.98B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 41 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more call options, than puts

Call options by funds: $6.14M | Put options by funds: $1.47M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

78% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 23

3% more capital invested

Capital invested by funds: $1.92B → $1.98B (+$65.2M)

12% less funds holding

Funds holding: 95 → 84 (-11)

58% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 19

Holders
84
Holders Change
-11
Holders Change %
-11.58%
% of All Funds
2.44%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
8
Increased
41
Reduced
23
Closed
19
Calls
$6.14M
Puts
$1.47M
Net Calls
+$4.67M
Net Calls Change
-$5.62M

Top Buyers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
+$15.9M
2
Capital Research Global Investors
Capital Research Global Investors
California
+$14.8M
3
BB
BB Biotech
Switzerland
+$8.56M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$7.78M
5
BIT
BlackRock Institutional Trust
California
+$7.73M

Top Sellers

Rank Fund Capital Flow
1
BCPEM
Bain Capital Public Equity Management
Massachusetts
-$16.9M
2
JHIU
Janus Henderson Investors US
Colorado
-$11.6M
3
PC
PointState Capital
New York
-$10.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.75M
5
EA
Emerald Advisers
Pennsylvania
-$4.98M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$6.41M +$647K +10,907 +12%
PAMU
27
Pictet Asset Management (UK)
United Kingdom
$6.32M -$273K -4,600 -4%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$6.28M +$1.11M +18,762 +24%
TCIM
29
TIAA CREF Investment Management
New York
$5.33M +$388K +6,531 +9%
EA
30
Emerald Advisers
Pennsylvania
$5.08M -$4.98M -83,952 -52%
Millennium Management
31
Millennium Management
New York
$4.63M +$4.24M +71,490 New
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$4.14M -$41.5K -700 -1%
GC
33
Guggenheim Capital
Illinois
$4.05M +$3.72M +62,607 New
JP Morgan Chase
34
JP Morgan Chase
New York
$4.05M +$3.14M +52,888 +549%
UBS AM
35
UBS AM
Illinois
$3.92M -$160K -2,700 -4%
BIM
36
BlackRock Investment Management
Delaware
$3.42M +$267K +4,506 +9%
Charles Schwab
37
Charles Schwab
California
$3.39M +$406K +6,846 +15%
BG
38
BlackRock Group
United Kingdom
$2.52M +$173K +2,909 +8%
Macquarie Group
39
Macquarie Group
Australia
$2.52M – – –
Invesco
40
Invesco
Georgia
$2.43M +$895K +15,078 +67%
Deutsche Bank
41
Deutsche Bank
Germany
$2.27M -$445K -7,494 -18%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$2.25M +$249K +4,200 +14%
Morgan Stanley
43
Morgan Stanley
New York
$2.03M +$899K +15,139 +93%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$1.9M +$940K +15,832 +117%
BlackRock
45
BlackRock
New York
$1.88M +$1.7M +28,649 +6,541%
TA
46
Teachers Advisors
New York
$1.7M +$158K +2,670 +11%
AC
47
Ascend Capital
California
$1.67M +$66.5K +1,120 +5%
MOACM
48
Mutual of America Capital Management
New York
$1.19M +$16.5K +278 +2%
Wells Fargo
49
Wells Fargo
California
$1.18M -$1.52M -25,683 -58%
American Century Companies
50
American Century Companies
Missouri
$1.17M -$4.75K -80 -0.4%
1
2
3 4 5

GEVA Hedge Fund Activity: Q4 2013 in Review

84 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q4 2013, worth a combined $1.98B — up 3.4% from $1.92B a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of GEVA and 8 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 41 added.

The largest buyer was Sectoral Asset Management, adding an estimated $15.9M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $16.9M sold.

  • 84 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q4 2013, down from 95 in Q3 2013.
  • Funds reported $1.98B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q4 2013, up 3.4% quarter-over-quarter.
  • 8 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q4 2013 and 19 closed out, a net change of -11 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q4 2013 was Sectoral Asset Management, an estimated $15.9M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q4 2013 was Bain Capital Public Equity Management, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2013.